226 articles
Quizartinib
Quizartinib (Vanflyta), a type II FLT3-ITD kinase inhibitor by Daiichi Sankyo, FDA-approved July 2023 with chemotherapy for newly diagnosed FLT3-ITD-positive AML; QuANTUM-First doubled median survival but carries QT/REMS cardiac restrictions.
Racemetyrosine
Racemetyrosine (SM-88, D/L-alpha-metyrosine, USAN 2019) is an unapproved racemic tyrosine analogue and tyrosine hydroxylase inhibitor investigated with methoxsalen, phenytoin, and sirolimus for pancreatic, prostate, and breast cancers.
Radotinib
Radotinib (Supect, IY5511HCl) is a second-generation Bcr-Abl and PDGFR tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia, approved only in South Korea (2012 salvage, 2015 first-line) and not reviewed by FDA or EMA.
Ranosidenib
Ranosidenib (HMPL-306) is HUTCHMED's oral dual inhibitor of mutant IDH1 and IDH2, blocking 2-hydroxyglutarate production. In Phase I R/R IDH-mutant AML it gave CR+CRh about 35% and is now in the China Phase III RAPHAEL trial versus salvage chemotherapy.
Recombinant human endostatin
Recombinant human endostatin (Endostar, 恩度, YH-16) is a soluble, N-terminally modified endostatin approved in China in 2005 for non-small cell lung cancer, unlike the insoluble wild-type endostatin whose US trials ended early.
Reparixin
Reparixin (repertaxin, DF 1681Y), Dompé's oral non-competitive allosteric CXCR1/CXCR2 (IL-8 receptor) inhibitor derived from ibuprofen; tested in transplant, breast cancer, and COVID-19 trials, not approved.
Repotrectinib
Repotrectinib (Augtyro, TPX-0005) is an oral ROS1/TRK/ALK kinase inhibitor approved by the FDA in 2023 for ROS1-positive NSCLC, including prior-TKI patients, and in 2024 for NTRK fusion-positive solid tumors.
Revumenib
Revumenib (Revuforj, SNDX-5613) is the first-in-class oral menin inhibitor from Syndax, FDA-approved in 2024 for relapsed/refractory KMT2A-rearranged acute leukemia and in 2025 for NPM1-mutated AML.
Rezivertinib mesylate (BPI-7711)
Rezivertinib mesylate (BPI-7711, 瑞必达, 甲磺酸瑞齐替尼胶囊) is a third-generation EGFR tyrosine kinase inhibitor from Beta Pharma, approved in China in May 2024 for EGFR T790M-mutated NSCLC after EGFR-TKI progression, dosed 180 mg once daily.
RGT-419B
RGT-419B, also known as GDC-4198, is an investigational oral CDK4/2 inhibitor for hormone receptor-positive breast cancer, acquired by Genentech for $850 million upfront in 2024.
RGT-587
RGT-587 (RG6795, GDC-0587) is Regor Therapeutics' brain-penetrant selective CDK4 inhibitor for HR+/HER2- breast cancer, acquired by Genentech/Roche in 2024 for $850M upfront; its Phase I trial was later terminated.
Ribociclib
Ribociclib (Kisqali, LEE011), a Novartis oral CDK4/6 inhibitor, treats HR+/HER2- breast cancer with endocrine therapy; FDA approved 2017 for metastatic disease (MONALEESA-2) and 2024 for adjuvant early breast cancer (NATALEE).
Rigosertib
Rigosertib (ON 01910.Na) is an investigational non-ATP-competitive anticancer drug, a benzyl styryl sulfone sodium salt targeting Plk1, PI3K, and Ras signaling; phase 3 MDS trials (ONTIME) showed no significant survival benefit.
Riviciclib
Riviciclib (P276-00) is a flavone-derived, ATP-competitive CDK1/4/9 inhibitor developed by Nicholas Piramal/Piramal Enterprises. It reached phase II trials in mantle cell lymphoma, melanoma, and head and neck cancer before development was discontinued.
Rivoceranib
Rivoceranib (apatinib, YN968D1) is an oral VEGFR-2 tyrosine kinase inhibitor approved in China for gastric cancer and, with camrelizumab, first-line liver cancer; not FDA approved, pending review.
Rocbrutinib
Rocbrutinib (LP-168, Luobutini) is Lupeng Pharmaceutical's oral fourth-generation BTK inhibitor with dual covalent and noncovalent binding, approved June 2026 in China for relapsed/refractory mantle cell lymphoma after BTK inhibitor exposure, with phase 3 ROCKET-CLL versus pirtobrutinib ongoing.
Rovadicitinib
Rovadicitinib (TQ05105, Anxu, 罗伐昔替尼) is a first-in-class oral JAK/ROCK dual inhibitor by Chia Tai Tianqing, first approved in China on 25 February 2026 as first-line therapy for intermediate-2 or high-risk myelofibrosis, and licensed globally to Sanofi.
Rucaparib
Rucaparib (Rubraca) is an oral PARP-1/2/3 inhibitor by pharmaand GmbH, FDA-approved for BRCA-mutated recurrent ovarian cancer maintenance and, since December 2025, BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor-directed therapy.
Ruxolitinib regimen
The ruxolitinib regimen is an oral protocol built around ruxolitinib, a selective JAK1 and JAK2 inhibitor, given alone or with azacitidine for myelofibrosis, related neoplasms, and graft-versus-host disease.
RV1001
RV1001 is an oral, selective PI3Kδ inhibitor developed by Rhizen Pharmaceuticals for canine lymphoma. Phase I/II trials in 56 dogs with B- and T-cell NHL showed 62% and 77% response rates, with manageable hepatotoxicity as the dose-limiting toxicity.
Saruparib
Saruparib (AZD5305) is AstraZeneca's orally bioavailable, PARP1-selective PARP inhibitor and trapper (~500-fold selectivity over PARP2) for HRR-deficient breast, ovarian, pancreatic, and prostate cancers, in Phase III EvoPAR trials.
Savolitinib
Savolitinib (volitinib, AZD6094, HMPL-504; Orpathys) is an oral, selective ATP-competitive MET tyrosine kinase inhibitor approved in China (2021) for MET exon 14-skipping NSCLC and developed with osimertinib for MET-amplified EGFR-mutant NSCLC and gastric cancer.
Selumetinib
Selumetinib (Koselugo, AZD6244, ARRY-142886) is an oral MEK1/2 inhibitor approved for NF1-related symptomatic inoperable plexiform neurofibromas in children and, since 2025, adults; 68% pediatric response in SPRINT, 20% vs 5% placebo in KOMET.
Semaxanib
Semaxanib (SU5416, semoxind) is a Sugen indolinone VEGFR2/c-kit tyrosine kinase inhibitor and angiogenesis inhibitor that failed phase III colorectal cancer testing and was discontinued in 2002, becoming the precursor of sunitinib.
Senaparib capsules
Senaparib capsules (Paishuning, 塞纳帕利胶囊), also IMP4297, are an oral PARP1/2 inhibitor by IMPACT Therapeutics approved in China January 2025 for first-line maintenance of advanced ovarian cancer, based on the FLAMES phase 3 trial.
Sitneprotafib
Sitneprotafib (JAB-3312, AST-24082) is Jacobio Pharma's oral allosteric SHP2 (PTPN11) inhibitor for cancer; second SHP2 inhibitor in FDA clinical development and first to reach Phase III, combined with glecirasib in KRAS G12C NSCLC.
Sitravatinib
Sitravatinib (MGCD516) is an oral multitargeted receptor tyrosine kinase inhibitor targeting TAM and split family kinases; tested with checkpoint inhibitors in RCC and NSCLC, its development was discontinued after Phase 3 trials missed their endpoints.
Sonidegib
Sonidegib, sold as Odomzo, is an oral Hedgehog pathway inhibitor, approved in the United States in 2015 for locally advanced basal cell carcinoma not treatable by surgery or radiation.
Sonrotoclax
Sonrotoclax (BGB-11417, Beqalzi) is BeOne Medicines' oral Bcl-2 inhibitor, FDA accelerated approval May 2026 for relapsed/refractory mantle cell lymphoma after BTK inhibitor therapy; ORR 52%.
Sorafenib regimen
The sorafenib regimen is an oral cancer treatment taking 400 mg of sorafenib (Nexavar) twice daily, approved for advanced liver, kidney, and radioactive iodine-refractory thyroid cancers.